AbbVie Stock - analyst eyes on Humira cliff and next earnings
22.06.2026 - 05:55:25 | ad-hoc-news.de
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 05:52 CET. Details in the imprint.
AbbVie (US00287Y1091) remains in a key transition year as it manages the ongoing Humira patent cliff and ramps up newer immunology and oncology therapies. With the next quarterly report approaching, investor focus centers on whether growth drivers can keep offsetting legacy declines.
All news and analysis on AbbVie stock
From earnings reports to pipeline updates, our AbbVie topic page bundles the latest headlines, filings and market data on the pharmaceutical group.
What recent results showed
In its most recent quarterly release, AbbVie reported that Humira sales continued to decline sharply in the United States after biosimilar competition arrived, while international revenue had already largely reset earlier. Newer immunology drugs Skyrizi and Rinvoq, however, posted robust double-digit growth and remained central to management's replacement strategy for Humira's lost revenue.
The company reiterated that combined Skyrizi and Rinvoq sales are expected to exceed Humira revenue at peak, underscoring how critical execution in immunology is for the long-term earnings profile. Management also highlighted continued contributions from oncology assets such as Imbruvica and Venclexta, even as some of these products face their own competitive pressures.
Weekly outlook on earnings and events
Looking ahead over the coming weeks, investors are watching for AbbVie's next scheduled earnings date on the U.S. calendar, which historically falls in late July for the second quarter and late October for the third quarter. Ahead of that release, trading in AbbVie shares is likely to be driven by incremental data points from clinical trials, regulatory milestones and peer read-across within large-cap pharma.
Consensus expectations compiled by market data providers currently anticipate modest top-line growth for the full year as new products scale while Humira continues to decline. On the earnings side, the Street generally models a gradual rebuild of adjusted EPS after the post-Humira trough, rather than a rapid snap-back, reflecting elevated R&D and marketing spend during the transition.
The product behind the stock
AbbVie generates most of its revenue from prescription medicines in immunology, oncology, neuroscience and aesthetics. A key current growth engine is Skyrizi, a monoclonal antibody for moderate to severe plaque psoriasis and Crohn's disease that has been gaining share against other biologics.
Where the stock trades today
AbbVie shares trade on the New York Stock Exchange under the ticker ABBV in U.S. dollars; at the time of the latest market close, the stock changed hands at a level consistent with a large-cap U.S. pharmaceutical peer and reflected the ongoing Humira-to-Skyrizi transition.
Key facts on AbbVie stock
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Venue: NYSE
- Price (as of last close): not precisely verified in real time USD
- Market cap: large-cap U.S. pharmaceutical (last reported in the hundreds of billions of USD)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
